Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, First-in-human, Single Agent, Dose Escalation Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442257 in Patients With Relapsed and Refractory Multiple Myeloma and Relapsed and Refractory Non-Hodgkin Lymphoma

NCT04401020 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04401020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04401020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, First-in-human, Single Agent, Dose Escalation Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442257 in Patients With Relapsed and Refractory Multiple Myeloma and Relapsed and Refractory Non-Hodgkin Lymphoma
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Terminated
Start date
July 24, 2020
Completion date
May 11, 2026
Enrollment
47 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm malignant